Stock Library / BLTE

BLTE Healthcare Latest YouTube: Q2 2026 Published 2026-08-17

Belite Bio, Inc

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

BLTE Stock Q2 2026: Belite Bio Earnings - The FDA Said Yes And The Stock Fell 7%

Published 2026-08-17

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-17

Podcast available

Yes

Current price

$161.06

-0.88 (-0.54%)

Trailing / Forward P/E

—

Forward: 75.21x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

—

Earnings: —

Margins

0.0% op

Gross: 0.0% · Net: 0.0%

Balance sheet

33.56x current

Debt / Equity: —

52-week range / Beta

$62.18 - $200.00

Beta: -1.23

Analyst target

$214.00

Upside: 32.9%

Cash / shareholder return

—

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 8.35x

Return on equity: -22.1%

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Price chart

Market context for BLTE

Competitive view

BLTE vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Belite Bio, Inc latest YouTube video thumbnail

Belite Bio, Inc

BLTE

YouTube Podbean

Latest video

Q2 2026

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

BLTE

$6.49B

Belite Bio, Inc

ISRG

$135.72B

Intuitive Surgical

JNJ

$651.25B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

BLTE

—

Belite Bio, Inc

ISRG

43.5x

Intuitive Surgical

JNJ

31.4x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

BLTE

75.2x

Belite Bio, Inc

ISRG

31.4x

Intuitive Surgical

JNJ

22.0x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

BLTE

—

Belite Bio, Inc

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

BLTE

—

Belite Bio, Inc

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

BLTE

0.0%

Belite Bio, Inc

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

BLTE

0.0%

Belite Bio, Inc

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

BLTE

0.0%

Belite Bio, Inc

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

BLTE

-22.1%

Belite Bio, Inc

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

BLTE

—

Belite Bio, Inc

ISRG

1.9%

Intuitive Surgical

JNJ

2.6%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

BLTE

—

Belite Bio, Inc

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

BLTE

33.56x

Belite Bio, Inc

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

BLTE

-1.23

Belite Bio, Inc

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

BLTE

—

Belite Bio, Inc

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

BLTE

32.9%

Belite Bio, Inc

ISRG

26.2%

Intuitive Surgical

JNJ

0.8%

Johnson & Johnson

Related research

Non-quarter videos featuring BLTE

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-17

BLTE Stock: Belite Bio Q2 2026 Earnings - FDA Said Yes, Stock Fell 7%

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for BLTE

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-17

Published youtube podcast complete

BLTE Stock Q2 2026: Belite Bio Earnings - The FDA Said Yes And The Stock Fell 7%

Quarterly earnings-analysis entry for Belite Bio, Inc. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music